COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Z Rodriguez, AL Shane, H Verkerke, C Lough… - Blood advances, 2020 - Elsevier
Blood advances, 2020•Elsevier
Methods The patient is blood group O RhD negative. Donor 1 is a 63-year-old male who
donated 35 days following COVID-19 symptom resolution and is blood type A RhD positive.
Donor 2 is a 56-year-old male who donated 55 days following COVID-19 symptom
resolution and is blood type O RhD negative. Both had mild COVID-19 infection, and neither
was hospitalized. The plasma donor units were transfused without prior characterization per
emergency use. To understand the impact of C19-CP treatment, both donor
donated 35 days following COVID-19 symptom resolution and is blood type A RhD positive.
Donor 2 is a 56-year-old male who donated 55 days following COVID-19 symptom
resolution and is blood type O RhD negative. Both had mild COVID-19 infection, and neither
was hospitalized. The plasma donor units were transfused without prior characterization per
emergency use. To understand the impact of C19-CP treatment, both donor
Methods
The patient is blood group O RhD negative. Donor 1 is a 63-year-old male who donated 35 days following COVID-19 symptom resolution and is blood type A RhD positive. Donor 2 is a 56-year-old male who donated 55 days following COVID-19 symptom resolution and is blood type O RhD negative. Both had mild COVID-19 infection, and neither was hospitalized. The plasma donor units were transfused without prior characterization per emergency use. To understand the impact of C19-CP treatment, both donor
Elsevier